Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
about
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectivesPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Atezolizumab for the treatment of non-small cell lung cancer.Immunotherapy for gastric cancers: emerging role and future perspectives.PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Immune checkpoint dysfunction in large and medium vessel vasculitis.Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Bone marrow-derived mesenchymal stem cells inhibit T follicular helper cell in lupus-prone mice.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Emerging molecular therapeutic targets for cholangiocarcinoma.Immune Checkpoint Inhibitors for Brain Metastases.The roles of the PD-1/PD-L1 pathway at immunologically privileged sites.Treatment of Low-Blast Count AML using Hypomethylating Agents.sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis.HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect.PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features.It's a long way to the top (if you want to personalize immunotherapy)Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).Immune checkpoint inhibitors in cancer therapy.Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.High-affinity human PD-L1 variants attenuate the suppression of T cell activation.Expression of programmed death ligand-1 on bladder tissues is detected in a clinically and histologically well-defined interstitial cystitis cohort.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.CD4+ T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective.Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.
P2860
Q33833832-D34DEEA7-CFEB-4F9D-8800-FD43D6EB3478Q33876861-FFB13790-9BEE-492C-B7C8-7DA890DDC240Q33884361-7E0ACD46-2AC0-49E7-948E-131DBFAB61E9Q34550012-FFE00077-261F-4BD7-9BE2-77209B429EA6Q36358014-A5B49A5E-27B2-4A19-B08C-6D360C895199Q38642853-56699E04-A4D0-490D-B0CC-409F1B9A1D80Q38657760-D7DD7FB3-CE60-4B2F-AF9D-56FA450D202DQ38675969-E9B4D068-BD83-47C5-A644-79A94C34096CQ38738652-C816A02E-CB0A-4F52-94A6-1AA8F518EA44Q38787346-2A98B81C-EC03-4643-8545-451C85A53E53Q38818283-7FC284F1-DA1E-4D5E-A385-F86D7AB92576Q38819982-85FAAE9A-687E-4D30-8F6C-75F3C6DFB8D3Q38897019-FB4B7CE5-4E61-46C6-8C7F-AD2F82A5DCD9Q39095285-4D7B89DE-4329-4F69-9328-BC37D63DD670Q39155259-1A27D31F-2539-4C59-AA15-10FA17F1C807Q39175665-BD839CB5-D935-4682-9554-47EEF1D64E89Q39227356-4B0B98F2-1E76-4A8B-BDA6-BCD90CD442DCQ39247421-3DB41156-25D8-46CC-8BF7-4407FE00FF44Q39354025-483BA735-9F59-40B8-ACF4-B9A233F810B8Q39429687-0E2374B3-4024-4ADB-A9F6-FFC013C89EDFQ40209273-73D3A998-9DDB-486E-93D3-63CD44AA08B1Q40483016-70D3292E-6A32-499C-9F23-C87A264FAE2FQ41538262-2E14719C-C095-4F97-8FFE-DA955694DC0AQ41926342-011D7615-0700-4F34-92BA-5AC7D6B11847Q42290503-C415A47F-90E2-4AC6-85D4-E69DAAC3B34BQ42330130-6812CF08-B5FC-4AC8-A0C0-89973033B0A5Q42378536-929C5941-8C2E-40BC-8CB7-33F2ABC36478Q45217684-2C8003A0-3A28-4A64-8DF7-6F5ECD078866Q45822425-CCFB6B3C-AAAB-45C4-8D59-F240150A53F4Q45871487-512BDE1F-4574-4323-BDF1-77E15DC4E331Q46096916-5E6EC3DD-024B-435A-979A-B8C531D63F75Q46708524-14731DC3-8D1E-42C4-A9DA-941912440C69Q47098333-D30E9178-129B-4A18-B448-FA5071FD7D81Q47123123-50BE39B0-FF02-4361-BE1D-7D1B9532DD3AQ47249076-97B38D88-7097-44D1-8BF1-DAF9F11C0F9FQ47329066-0D00B0CC-CA17-40BF-B589-6C49684C916BQ47372804-4CBB4C49-7634-4DF5-A135-49E90796EA69Q47379536-3981F2F6-C49D-4B80-92C3-8A00F9C8F916Q47580241-E685F3D3-DD28-401E-900B-E947BCFD6E10Q47608535-0B142D08-383C-47E1-A7F5-4761E3513994
P2860
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
@en
type
label
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
@en
prefLabel
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
@en
P2860
P356
P1476
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
@en
P2093
Vassiliki A Boussiotis
P2860
P304
P356
10.1056/NEJMRA1514296
P407
P577
2016-11-01T00:00:00Z